Standard Contracts
RESTRICTED STOCK UNIT AGREEMENTRestricted Stock Unit Agreement • November 5th, 2010 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • North Carolina
THIS AGREEMENT (this “Agreement”) is made effective this 15th day of September, 2010 (the “Date of Grant”) by and between Inspire Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Charles A. Johnson (the “Grantee”).
AMENDED AND RESTATED LICENSE, DEVELOPMENT AND MARKETING AGREEMENT BETWEEN INSPIRE PHARMACEUTICALS, INC. AND ALLERGAN, INC. ORIGINALLY DATED AS OF JUNE 22, 2001 AND AMENDED AND RESTATED AUGUST 19, 2010License, Development and Marketing Agreement • November 5th, 2010 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED LICENSE, DEVELOPMENT AND MARKETING AGREEMENT (this “Agreement”), made and entered into originally as of June 22, 2001, as amended and restated as of August 19, 2010 (the “Restatement Date”), is entered into by and between Inspire Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware, having offices located at 4222 Emperor Boulevard, Suite 470, Durham, North Carolina 27703 (“Inspire”), and Allergan, Inc., a corporation organized under the laws of Delaware, having offices located at 2525 Dupont Drive, Irvine, California 92612 and its affiliates, Allergan Sales, Inc. and Allergan Pharmaceuticals Holdings (Ireland) Ltd. (collectively, “Allergan”). This Agreement as amended and restated as of the Restatement Date amends and restates (and replaces and supersedes) in its entirety the Original Agreement (defined below) as originally executed and previously amended, unless otherwise specifically provided for in this Agreeme
STOCK OPTION AGREEMENTStock Option Agreement • November 5th, 2010 • Inspire Pharmaceuticals Inc • Pharmaceutical preparations • North Carolina
THIS AGREEMENT (this “Agreement”) is made effective this 15th day of September, 2010 (the “Date of Grant”) by and between Inspire Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Charles A. Johnson (the “Grantee” or “Executive”).
